Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2025-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物独立董事年度述职报告（WEN CHEN）
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2024 for a company named 益方生物科技（上海）股份有限公司. It details the director's background, attendance at meetings, oversight activities, review of financial reports, and governance matters. It is a narrative report on the director's duties and observations rather than a financial report, audit report, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement or proxy material. This type of document fits best under Board/Management Information (MANG) as it relates to board member activities and governance oversight by a director.
2025-04-25 Chinese
益方生物关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in the company's accounting policies based on new accounting standards issued by the Ministry of Finance. It explicitly states that these changes do not have a material impact on the company's financial condition or operating results. The document is a formal disclosure by the company's board but does not contain financial statements or detailed financial data. It is not an annual or interim report, audit report, or earnings release. It is a regulatory announcement about accounting policy changes, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance disclosure.
2025-04-25 Chinese
益方生物第二届董事会2025年第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the company's second board meeting in 2025. It details the meeting date, attendance, and voting results on various agenda items including approval of the 2024 annual report, financial statements, profit distribution plan, and other reports. The document repeatedly states that these reports have been or will be disclosed separately on the Shanghai Stock Exchange website and that some matters will be submitted to the shareholders' meeting for approval. The document itself does not contain the full annual report or detailed financial statements but rather summarizes board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters. The document length is under 5,000 characters and it is not a report publication announcement since it contains substantive board meeting content and resolutions rather than just a notice of report availability.
2025-04-25 Chinese
益方生物董事会审计委员会对会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm (立信会计师事务所) for the 2024 annual audit. It details the auditor's qualifications, the audit process, communication with management, and the audit committee's evaluation of the auditor's performance. It references the 2024 annual financial report audit and internal control audit but does not contain the full annual report or financial statements itself. The document is focused on the audit oversight and the auditor's performance, which aligns with the definition of an Audit Report / Information (AR). The document length is 2425 characters, which is relatively short but contains substantive information about the audit process and results, not just an announcement or certification. Therefore, it is classified as an Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
益方生物第二届监事会2025年第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Yifang Bio-Technology (Shanghai) Co., Ltd. regarding the resolutions passed at the second meeting of the second Supervisory Board in 2025. It includes details about the meeting, voting results on various agenda items such as the 2024 Supervisory Board work report, the 2024 annual report and summary, the 2024 financial final accounts report, the 2024 profit distribution plan, and a special report on the use of raised funds. The document is an official announcement of board resolutions and meeting outcomes, not the full annual report or financial statements themselves. It is a regulatory announcement related to board/management decisions but specifically from the Supervisory Board, which aligns with Board/Management Information filings. The document length is short (1239 characters), and it is an announcement of meeting resolutions rather than the full report or financial data. Therefore, the best classification is Board/Management Information (MANG).
2025-04-25 Chinese
益方生物2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled "益方生物科技（上海）股份有限公司 2024 年年度报告摘要" which translates to "InventisBio (Shanghai) Co., Ltd. 2024 Annual Report Summary." It contains detailed information about the company's business, products, financial performance, risk factors, industry overview, and future plans. The text references the full annual report and encourages investors to read the full report on the official website. It includes financial data such as net losses, cumulative losses, and profit distribution plans for the year 2024. The document also mentions an unqualified audit opinion from a certified public accounting firm. The length of the document is substantial (15,000 characters), and it contains substantive financial and operational data, not just an announcement or summary. Therefore, this document is the Annual Report itself or a detailed summary of it, fitting the category of Annual Report (10-K). FY 2024
2025-04-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.